NDC 0409-1626-02 Butorphanol Tartrate

Butorphanol Tartrate

NDC Package Code 0409-1626-02

The NDC Code 0409-1626-02 is assigned to a package of 10 vial, single-dose in 1 carton > 2 ml in 1 vial, single-dose (0409-1626-42) of Butorphanol Tartrate, a human prescription drug labeled by Hospira, Inc.. The product's dosage form is injection, solution and is administered via intramuscular; intravenous form.

Field Name	Field Value
NDC Code	0409-1626-02
Package Description	10 VIAL, SINGLE-DOSE in 1 CARTON > 2 mL in 1 VIAL, SINGLE-DOSE (0409-1626-42)
Proprietary Name	Butorphanol Tartrate What is the Proprietary Name? The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
Non-Proprietary Name	Butorphanol Tartrate What is the Non-Proprietary Name? The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
11-Digit NDC Billing Format	00409162602 NDC Format for Billing For insurance billing purposes the Centers for Medicare & Medicaid Services (CMS) created an 11 digit NDC derivative identifier. If the NDC Package code is less than 11 digits the code must be padded with leading zeros. The leading zeros must be added to the appropriate segment to create a 5-4-2 configuration.
Billing Unit	ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
Product Type	Human Prescription Drug What kind of product is this? Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
Labeler Name	Hospira, Inc.
Dosage Form	Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route(s)	Intramuscular - Administration within a muscle. Intravenous - Administration within or into a vein or veins. Intramuscular - Administration within a muscle. Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)	BUTORPHANOL TARTRATE 2 mg/mL BUTORPHANOL TARTRATE 2 mg/mL
Pharmacological Class(es)	Competitive Opioid Antagonists - [MoA] (Mechanism of Action) Opioid Agonist/Antagonist - [EPC] (Established Pharmacologic Class) Partial Opioid Agonists - [MoA] (Mechanism of Action) Competitive Opioid Antagonists - [MoA] (Mechanism of Action) Opioid Agonist/Antagonist - [EPC] (Established Pharmacologic Class) Partial Opioid Agonists - [MoA] (Mechanism of Action)
DEA Schedule	Schedule IV (CIV) Substances What is the Drug Enforcement Administration (DEA) CIV Schedule? The controlled substances in the CIV schedule have an abuse potential and dependence liability less than those listed in CIII and have an accepted medical use in the United States.
Sample Package	No Sample Package? This field Indicates whether this package is a sample packaging or not.
Marketing Category	ANDA - A product marketed under an approved Abbreviated New Drug Application. What is the Marketing Category? Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
FDA Application Number	ANDA074626 What is the FDA Application Number? This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Start Marketing Date	12-20-2005 What is the Start Marketing Date? This is the date that the labeler indicates was the start of its marketing of the drug product.
Listing Expiration Date	12-31-2020 What is the Listing Expiration Date? This is the date when the listing record will expire if not updated or certified by the product labeler.

NDC Code Structure

0409 - Hospira, Inc.
- 0409-1626 - Butorphanol Tartrate
  - 0409-1626-02 - 10 VIAL, SINGLE-DOSE in 1 CARTON

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the disclaimer below.

NDC HCPCS Crosswalk

This crosswalk is intended to help the public understand which drug products (identified by NDCs) are assigned to which HCPCS billing codes.

NDC 0409-1626-02 HCPCS crosswalk information with package details and bill units information.

NDC Billing Code	HCPCS Code	HCPCS Code Desc.	Dosage	Package Size	Package Quantity	Billable Units	Billable Units / Pkg
00409162602	J0595	Butorphanol tartrate 1 mg	1 MG	2	10	4	40

* Please review the disclaimer below.

Other Product Packages

The following packages are also available for Butorphanol Tartrate with product NDC 0409-1626.

NDC Package Code	Package Description
0409-1626-01	10 VIAL, SINGLE-DOSE in 1 CARTON > 1 mL in 1 VIAL, SINGLE-DOSE (0409-1626-21)
0409-1626-10	10 VIAL, SINGLE-DOSE in 1 CARTON > 1 mL in 1 VIAL, SINGLE-DOSE (0409-1626-09)

* Please review the disclaimer below.

Previous Code
0409-1626

Next Code
0409-1630